生物试剂
>
生化试剂
>
信号通路
> VcMMAE
加入收藏 取消收藏

VcMMAE  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：1mg 5mg 10mg 25mg in glass bottle
溶解性：溶于DMSO（≥ 54 mg/mL）
产品描述：基本信息 产品编号： V10096  产品名称： VcMMAE CAS: 646502-53-6   储存条件 粉末 2-8℃ 四年     分子式： C68H105N11O15 溶于液体 -80℃ 两年 分子量 1316.63     化学名：  Maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl monomethylauristatin E Solubility (25°C)：   体外:   DMSO 100 mg/mL (75.95mM) Ethanol 100 mg/mL (75.95mM) Water Insoluble 体内(现配现用):   ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 0.7595mL 3.7976mL 7.5951mL 5mM 0.1519mL 0.7595mL 1.5190mL 10mM 0.0760mL 0.3798mL 0.7595mL 50mM 0.0152mL 0.0760mL 0.1519mL   生物活性 产品描述 抗体偶联药物的一部分 (drug-linker conjugate for ADC)，具有抗癌活性，它由 MMAE (一种 tubulin 抑制剂) 和 Vc 连接而成。 靶点 Auristatin 体外研究 Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells. MMAE sensitized colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells 体内研究 Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolonged tumor regression in xenograft models   推荐实验方法(仅供参考) Cell Assay Monomethyl auristatin E (MMAE, 5nM) and ionizing radiation (IR) treated cells are harvested and lysed in RIPA buffer with protease and phosphatase inhibitors. 30μg of lysate undergo electrophoresis using 4-12% Bis-Tris gels, transferred to PVDF membranes and incubated with indicated primary antibodies. Blots are developed by ECL.   Animal Administration 6-8 week old female athymic nu/nu mice are injected subcutaneously into thighs with 5×106 HCT-116 or PANC-1 cells in a 1:1 Matrigel and PBS solution. Mice are treated with IR or intravenous (IV) injection of ACPP-cRGD-MMAE (6 nmoles/day, 18nmoles total, i.v.), tumor tissue is harvested, formalin fixed and paraffin embedded followed by staining with indicated antibodies. The primary antibody is used at a 1:250 dilution and is visualized using DAB as a chromagen with the UltraMap system.
保存条件：2-8℃ 充氮保存

猜你喜欢